Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma

Blood (2024) 144 (Supplement 1): 4361.

https://doi.org/10.1182/blood-2024-201598

Published: 2024

Journal Articles

Genetic Subtyping Using Whole Exome Sequencing across Large B Cell Lymphoma Entities in a Series of 109 DLBCL and Plasmablastic Lymphoma Cases

Santiago Montes-Moreno, Sr., Aitana Avendaño, Sonia Gonzalez De Villambrosia, Laura Rodriguez-Merino, Jordi Morata, Raul Tonda, Estrella Carrillo-Cruz, Carlos Grande, Jose Maria Roncero, Jaime Perez De Oteyza, Concepcion Nicolas, Beatriz Rey Búa, Pau Abrisqueta, Antonio Gutierrez, Angel Ramirez, Alejandro Martin Garcia-Sancho, Eva Maria Gonzalez Barca

Blood (2023) 142 (Supplement 1): 6092.

https://doi.org/10.1182/blood-2023-179150

Published: 2023

Journal Articles

Idiopathic Multicentric Castleman Disease Interactive Disease Awareness and Educational Tool for Pathologists

Elena Sabattini, Jadee Neff, Daisy Alapat, Thomas Tousseyn, Grzegorz Rymkiewicz, Henrique Moura de Paula, Kateřina Kamarádová, Santiago Montes Moreno, Stephen Lade

Blood (2022) 140 (Supplement 1): 13033–13034.

https://doi.org/10.1182/blood-2022-169712

Published: 2022

Journal Articles

Cell Free Tumor DNA for DLBCL Genotyping in a Phase II Randomized Trial Comparing Standard RCHOP Versus Brcap As First Line Treatment in Patients with Poor IPI DLBCL

Nerea Martinez, PhD, Sonia González de Villambrosia, MD, Ainara Pereña, Raul Tonda, Sergi Beltran, PhD, Marta Gut, PhD, Estrella Carrillo-Cruz, MD, Carlos Grande, MD, Alejandro Martín, MD, Concepcion Nicolas, MD, Jose Maria Roncero, MD, Maria J. Rodriguez-Salazar, MD, Jaime Perez De Oteyza, MDPhD, Eulogio Conde, MD PhD, Eva Gonzalez-Barca, Santiago Montes-Moreno, MD PhD

Blood (2018) 132 (Supplement 1): 1676.

https://doi.org/10.1182/blood-2018-99-113757

Published: 2018

Journal Articles

Lenalidomide in Combination with R-ESHAP (LR-ESHAP) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Who Are Candidates for Autologous Stem-Cell Transplantation: A Phase 2 Study from the Spanish Group Geltamo

Alejandro Martín, MD PhD, Mónica Baile, MD, Guillermo Rodríguez, MD, Ivan Dlouhy, MD, Juan Manuel Sancho, MD PhD, Isidro Jarque, MD, Eva González-Barca, MD PhD, Antonio Salar, MD PhD, Manuel Espeso, Carlos Grande, MD PhD, Juan Bergua, MD, Santiago Montes-Moreno, MD, Armando Lopez-Guillermo, Dolores Caballero, MD PhD

Blood (2016) 128 (22): 1850.

https://doi.org/10.1182/blood.V128.22.1850.1850

Published: 2016

Journal Articles

Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisone) As First Line Treatment in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo

Blood (2016) 128 (22): 4201.

https://doi.org/10.1182/blood.V128.22.4201.4201

Published: 2016

Journal Articles

Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamicine and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis

Blood (2015) 126 (23): 1514.

https://doi.org/10.1182/blood.V126.23.1514.1514

Published: 2015

Journal Articles

B Cell Lymphoma Unclassifiable, with Features Intermediate Between Diffuse Large B Cell Lymphoma and Burkitt Lymphoma and Diffuse Large B Cell Lymphoma NOS with Doble/Triple Translocations: Immunophenotypic Analysis

Sonia González de Villambrosia, Mercedes Colorado, Andres Insunza, Ana Batlle, Brenda López-Pereira, Guillermo Martin, Paloma Ibarrondo, Santiago Montes-Moreno, Eulogio Conde, MD PhD

Blood (2015) 126 (23): 5037.

https://doi.org/10.1182/blood.V126.23.5037.5037

Published: 2015

Journal Articles

Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program

Blood (2014) 124 (21): 143.

https://doi.org/10.1182/blood.V124.21.143.143

Published: 2014

Journal Articles

NF-κB Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program

Blood (2014) 124 (21): 1620.

https://doi.org/10.1182/blood.V124.21.1620.1620

Published: 2014

Journal Articles

MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program

Blood (2013) 122 (21): 363.

https://doi.org/10.1182/blood.V122.21.363.363

Published: 2013

Journal Articles

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program

Blood (2013) 122 (15): 2630–2640.

https://doi.org/10.1182/blood-2012-12-473702

Published: 2013

Includes: Supplemental data

Journal Articles

Single nucleotide variation in the TP53 3′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program

Blood (2013) 121 (22): 4529–4540.

https://doi.org/10.1182/blood-2012-12-471722

Published: 2013

Includes: Supplemental data

Journal Articles

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Blood (2013) 121 (20): 4021–4031.

https://doi.org/10.1182/blood-2012-10-460063

Published: 2013

Includes: Supplemental data

Journal Articles

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Blood (2013) 121 (14): 2715–2724.

https://doi.org/10.1182/blood-2012-10-461848

Published: 2013

Includes: Supplemental data

Journal Articles

SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms

Santiago Montes-Moreno, Rocio Ramos-Medina, Azahara Martínez-López, Carlos Barrionuevo Cornejo, Alejandro Parra Cubillos, Shirley Quintana-Truyenque, Socorro María Rodriguez Pinilla, Raquel Pajares, Lydia Sanchez-Verde, Jorge Martinez-Torrecuadrada, Giovanna Roncador, Miguel Angel Piris

Blood (2013) 121 (4): 643–647.

https://doi.org/10.1182/blood-2012-08-447599

Published: 2013

Includes: Supplemental data

Journal Articles

Preferential Acquision of N-Glycosylation Sites in the VDJ Region in Germinal Center B-Cell-Like Difusse Large B-Cell Lymphoma

Miguel Alcoceba, Elena Sebastián, Ana Balanzategui, Luis Marín, Santiago Montes-Moreno, Teresa Flores, Noemí Puig, M. Eugenia Sarasquete, M. Carmen Chillón, Cristina Jiménez, Rocío Corral, Eva González-Barca, M. Dolores Caballero, Jesús F. San Miguel, Ramón García-Sanz, Marcos González

Blood (2012) 120 (21): 1589.

https://doi.org/10.1182/blood.V120.21.1589.1589

Published: 2012

Journal Articles

Risk Adapted-High Dose Therapies Modulate the Impact of Biological Classification in Diffuse Large B Cell Lymphoma Prognosis. Analysis of Biological Markers in Patients From Clinical Trials in Geltamo and Gotel Spanish Collaborative Groups.

Blood (2012) 120 (21): 2672.

https://doi.org/10.1182/blood.V120.21.2672.2672

Published: 2012

Journal Articles

Prognostic Significance and Phenotypic Manifestations of MYC/BCL2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Extranodal Organ Involvement: A Report of the International DLBCL Rituximab-CHOP Consortium Program Study

Blood (2012) 120 (21): 544.

https://doi.org/10.1182/blood.V120.21.544.544

Published: 2012

Journal Articles

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

Blood (2012) 120 (19): 3986–3996.

https://doi.org/10.1182/blood-2012-05-433334

Published: 2012

Includes: Supplemental data

NARROW

Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma

Genetic Subtyping Using Whole Exome Sequencing across Large B Cell Lymphoma Entities in a Series of 109 DLBCL and Plasmablastic Lymphoma Cases

Idiopathic Multicentric Castleman Disease Interactive Disease Awareness and Educational Tool for Pathologists

Cell Free Tumor DNA for DLBCL Genotyping in a Phase II Randomized Trial Comparing Standard RCHOP Versus Brcap As First Line Treatment in Patients with Poor IPI DLBCL

Lenalidomide in Combination with R-ESHAP (LR-ESHAP) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Who Are Candidates for Autologous Stem-Cell Transplantation: A Phase 2 Study from the Spanish Group Geltamo

Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisone) As First Line Treatment in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo

Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamicine and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis

B Cell Lymphoma Unclassifiable, with Features Intermediate Between Diffuse Large B Cell Lymphoma and Burkitt Lymphoma and Diffuse Large B Cell Lymphoma NOS with Doble/Triple Translocations: Immunophenotypic Analysis

Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program

NF-κB Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program

MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program

Single nucleotide variation in the TP53 3′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms

Preferential Acquision of N-Glycosylation Sites in the VDJ Region in Germinal Center B-Cell-Like Difusse Large B-Cell Lymphoma

Risk Adapted-High Dose Therapies Modulate the Impact of Biological Classification in Diffuse Large B Cell Lymphoma Prognosis. Analysis of Biological Markers in Patients From Clinical Trials in Geltamo and Gotel Spanish Collaborative Groups.

Prognostic Significance and Phenotypic Manifestations of MYC/BCL2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Extranodal Organ Involvement: A Report of the International DLBCL Rituximab-CHOP Consortium Program Study

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only